Mentor Capital (MNTR) Invests in Leading-Edge Cancer Therapy & Drug Development Companies

MNTR's objective is to help defeat cancer by funding $125 Million into the best new cancer fighting companies. MNTR equity is targeted to the critical gap between non-profit discovery and Big-Pharma sales.

To inject funds into the cancer companies (rather than trade in the market) MNTR seeks to directly acquire and escrow $125 Million in shares from fifteen Cancer Index or other leading firms. Any resulting net exercise in MNTR’s $125 Million in freely tradable warrants are paid out pro rata to the cancer fighters under MNTR’s standard Long-Term Equity Funding Contract.

Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013

Mentor Capital Telemedicine Investee Sales Double

Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013

Mentor Capital Telemedicine Investee Projects $1.0 Million Profit

More...